Young children (between 30 and 37 months in age) repeated single words, and these words were transcribed by listeners.
Lapin recounts that he could sense the tension rising as his autistic client’s behavior started escalating after he had been triggered by something in the store.
Their mission is to address the behavioral, psychological, and emotional needs of individuals with disabilities using therapeutic approaches that assure continued participation in supported society.
Anastasis is a recently described process in which cells recover after late-stage apoptosis activation. The functional consequences of anastasis for cells and tissues are not clearly understood.
Individuals with Down syndrome are at higher risk of developing Alzheimer’s disease, and it typically presents it at an earlier age than the general population. It is estimated that 90% of people with Down syndrome will have developed Alzheimer’s by age 65.
LEND trainees, including graduate students, self-advocates, and families, learn to explore perspectives in disability they might not otherwise experience.
One mutation in a single gene, as straightforward as it may sound, can cause a broad range of symptoms and severity among those who carry it. This is the case for fragile X syndrome (FXS), the most common hereditary form of intellectual disability.
Community TIES (Training, Intervention, and Evaluation Services) is a UW-Waisman Center behavioral support program that serves residents of Dane County with intellectual and developmental disabilities and their families.
For the next hour, Rivera-Bonet and Montoto spoke with Qiang Chang, PhD, director of the Waisman Center, and Paola Perez, MSSW, social worker and Waisman Center clinics operations manager, about the Waisman Center and its broad range of research, resources, and services for individuals with intellectual and developmental disabilities and their families.
People with Down Syndrome (DS) are at high risk for Alzheimer’s disease (AD) because of their unique biology and provide an unparalleled opportunity to develop biomarkers of preclinical AD.